Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Anticholinergic drug used as spasmolytic for functional gastrointestinal disorders.
At latest update relevant published data on excretion into breast milk were not found.
It acts locally on the intestinal mucosa. Absorption through the intestine is practically absent (Evangelista 2004, Catalogo 2008), with an excretion being almost 100% unmodified in feces that is determinant for the extremely low levels reached in the plasma (Zhao 2010: <0.02 mg / L), which causes the passage through breastmilk in significant amounts must be very unlikely.
Side effects are mild and very rarely seen.
Although anticholinergics may reduce milk production, however, because of its poor absorption it would not be the case with Otilonium.